Subcutaneous abatacept versus intravenous abatacept : a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
(2011) Arthritis & Rheumatism — Vol. 63, n° 10, p. 2854-2864 (2011)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 414.62 KB
Details
- Authors
- Abstract
- To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept.
- Affiliations
Citations
Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon-Campos, J. A., Porawska, W., Box, J., Legerton, C., Nasonov, E., Durez, P., Aranda, R., Pappu, R., Delaet, I., Teng, J., & Alten, R. (2011). Subcutaneous abatacept versus intravenous abatacept : a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis & Rheumatism, 63(10), 2854-2864. https://doi.org/10.1002/art.30463 (Original work published 2011)